Key Takeaways Exelixis' Q3 earnings of $0.78 per share topped estimates and rose from$0.47 a year ago.Revenues grew 10.8% to $598M, driven by higher Cabometyx sales and strong product demand.EXEL narrows 2025 revenue outlook to$2.30-$2.35B and expands its stock repurchase program.Exelixis, Inc. (EXEL) reported better-than-expected results for the third quarter of 2025.Adjusted earnings of 78 cents per share beat the Zacks Consensus Estimate of 68 cents. The company registered adjusted earnings of 47 cents ...